Patients’ characteristics according to first vs second remission at diagnosis and before allogeneic HSCT
| . | All patients n = 580 . | HSCT in first CR/CRi n = 460 . | HSCT in second CR/CRi n = 120 . | P . |
|---|---|---|---|---|
| Characteristics at diagnosis | ||||
| Sex, n (%) | .68 | |||
| Male | 308 | 242 (53) | 66 (55) | |
| Female | 272 | 218 (47) | 54 (45) | |
| Disease origin, n (%) | .002 | |||
| Secondary/treatment related | 195 | 169 (37) | 26 (22) | |
| De novo | 385 | 291 (63) | 94 (78) | |
| Hemoglobin, g/dL, median (range) | 8.9 (3.2-15.7) | 8.7 (3.2-15.7) | 9.5 (4.3-14.9) | .01 |
| Platelet count, x 109/L, median (range) | 65 (1-950) | 65 (1-950) | 65 (3-289) | .98 |
| WBC, × 109/L, median (range) | 5.9 (0.1-385) | 5.4 (0.1-385) | 17.1 (0.6-366) | .006 |
| <10 × 109/L, n (%) | 118 | 199 (63) | 19 (40) | .002 |
| ≥10 × 109/L, n (%) | 144 | 115 (37) | 29 (60) | |
| Blood blasts, %, median (range) | 21 (0-98) | 20 (0-98) | 31 (0-92) | .16 |
| BM blasts, %, median (range) | 51 (0-95) | 50 (0-95) | 61 (22-95) | .03 |
| CD34+/CD38− cell burden, median (range) | 0.5 (0-89) | 0.5 (0-89) | 0.5 (0-21) | .77 |
| Normal karyotype, n (%) | <.001 | |||
| Absent | 288 | 253 (59) | 35 (34) | |
| Present | 247 | 178 (41) | 69 (66) | |
| ELN2017 group, n (%) | .15 | |||
| Favorable | 112 | 89 (25) | 23 (34) | |
| Intermediate | 147 | 123 (34) | 24 (36) | |
| Adverse | 168 | 148 (41) | 20 (30) | |
| Complex karyotype, n (%) | <.001 | |||
| Absent | 445 | 346 (84) | 99 (100) | |
| Present | 67 | 67 (16) | 0 (0) | |
| Monosomal karyotype, n (%) | <.001 | |||
| Absent | 459 | 359 (87) | 100 (98) | |
| Present | 58 | 56 (13) | 2 (2) | |
| NPM1, n (%) | .03 | |||
| Wild-type | 328 | 280 (77) | 48 (65) | |
| Mutated | 108 | 82 (23) | 26 (35) | |
| FLT3-ITD, n (%) | <.001 | |||
| Wild-type | 345 | 298 (81) | 47 (63) | |
| Mutated | 96 | 68 (19) | 28 (37) | |
| NPM1 and FLT3-ITD co-mutation, n (%) | .01 | |||
| NPM1 wild-type, FLT3-ITD negative | 281 | 246 (68) | 35 (47) | |
| NPM1 mutated, FLT3-ITD negative | 61 | 49 (14) | 12 (16) | |
| NPM1 wild-type, FLT3-ITD positive | 47 | 34 (9) | 13 (18) | |
| NPM1 mutated, FLT3-ITD positive | 45 | 31 (9) | 14 (19) | |
| CEBPAbiallelic, n (%) | .08 | |||
| Wild-type | 344 | 292 (99) | 52 (95) | |
| Mutated | 7 | 4 (1) | 3 (5) | |
| FLT3-ITD allelic ratio, n (%) | .23 | |||
| <0.5 | 46 | 36 (59) | 10 (43) | |
| ≥0.5 | 38 | 25 (41) | 13 (57) | |
| RUNX1, n (%) | .32 | |||
| Wild-type | 103 | 87 (86) | 16 (76) | |
| Mutated | 19 | 14 (14) | 5 (24) | |
| TP53, n (%) | >.99 | |||
| Wild-type | 109 | 90 (89) | 19 (90) | |
| Mutated | 13 | 11 (11) | 2 (10) | |
| ASXL1, n (%) | .73 | |||
| Wild-type | 114 | 94 (89) | 20 (87) | |
| Mutated | 15 | 12 (11) | 3 (13) | |
| Characteristics at HSCT | ||||
| Age at HSCT, y, median (range) | 59.6 (16.3-76.8) | 60.3 (16.3-76.0) | 59.6 (19.2-76.8) | .43 |
| Treatment cycles before HSCT, n (%) | <.001 | |||
| 1 | 157 | 72 (16) | 85 (71) | |
| 2 | 311 | 280 (61) | 31 (26) | |
| ≥3 | 111 | 107 (24) | 4 (3) | |
| Blood count regeneration at HSCT, n (%) | .41 | |||
| CR | 484 | 387 (84) | 97 (81) | |
| CRi | 96 | 73 (16) | 23 (19) | |
| MRD status at HSCT, n (%) | .10 | |||
| MRD− | 167 | 133 (58) | 34 (47) | |
| MRD+ | 133 | 95 (42) | 38 (53) | |
| Donor type, n (%) | .02 | |||
| Matched related | 124 | 109 (24) | 15 (13) | |
| Unrelated, HLA matched | 329 | 258 (56) | 71 (59) | |
| HLA mismatched | 112 | 80 (17) | 32 (27) | |
| Haploidentical | 14 | 12 (3) | 2 (2) | |
| Conditioning regimen, n (%) | .22 | |||
| NMA | 383 | 296 (64) | 87 (73) | |
| HSCT | 36 | 31 (7) | 5 (4) | |
| MAC | 161 | 133 (29) | 28 (23) | |
| HCT-CI score, n (%) | .59 | |||
| 0 | 244 | 195 (44) | 49 (42) | |
| 1 and 2 | 163 | 125 (26) | 38 (32) | |
| ≥3 | 159 | 129 (29) | 30 (26) | |
| CMV status, n (%) | .05 | |||
| Recipient+/donor− | 210 | 157 (35) | 53 (45) | |
| All others | 364 | 298 (65) | 66 (55) | |
| aGvHD ≥ grade 2, n (%) | .21 | |||
| Absent | 371 | 303 (74) | 68 (68) | |
| Present | 137 | 105 (26) | 32 (32) | |
| cGvHD, n (%) | .51 | |||
| Absent | 165 | 139 (41) | 26 (37) | |
| Limited | 58 | 45 (13) | 13 (19) | |
| Extended | 184 | 153 (45) | 31 (44) | |
| Donor sex, n (%) | .88 | |||
| All others | 489 | 388 (85) | 101 (86) | |
| Female into male | 82 | 66 (15) | 16 (14) | |
| . | All patients n = 580 . | HSCT in first CR/CRi n = 460 . | HSCT in second CR/CRi n = 120 . | P . |
|---|---|---|---|---|
| Characteristics at diagnosis | ||||
| Sex, n (%) | .68 | |||
| Male | 308 | 242 (53) | 66 (55) | |
| Female | 272 | 218 (47) | 54 (45) | |
| Disease origin, n (%) | .002 | |||
| Secondary/treatment related | 195 | 169 (37) | 26 (22) | |
| De novo | 385 | 291 (63) | 94 (78) | |
| Hemoglobin, g/dL, median (range) | 8.9 (3.2-15.7) | 8.7 (3.2-15.7) | 9.5 (4.3-14.9) | .01 |
| Platelet count, x 109/L, median (range) | 65 (1-950) | 65 (1-950) | 65 (3-289) | .98 |
| WBC, × 109/L, median (range) | 5.9 (0.1-385) | 5.4 (0.1-385) | 17.1 (0.6-366) | .006 |
| <10 × 109/L, n (%) | 118 | 199 (63) | 19 (40) | .002 |
| ≥10 × 109/L, n (%) | 144 | 115 (37) | 29 (60) | |
| Blood blasts, %, median (range) | 21 (0-98) | 20 (0-98) | 31 (0-92) | .16 |
| BM blasts, %, median (range) | 51 (0-95) | 50 (0-95) | 61 (22-95) | .03 |
| CD34+/CD38− cell burden, median (range) | 0.5 (0-89) | 0.5 (0-89) | 0.5 (0-21) | .77 |
| Normal karyotype, n (%) | <.001 | |||
| Absent | 288 | 253 (59) | 35 (34) | |
| Present | 247 | 178 (41) | 69 (66) | |
| ELN2017 group, n (%) | .15 | |||
| Favorable | 112 | 89 (25) | 23 (34) | |
| Intermediate | 147 | 123 (34) | 24 (36) | |
| Adverse | 168 | 148 (41) | 20 (30) | |
| Complex karyotype, n (%) | <.001 | |||
| Absent | 445 | 346 (84) | 99 (100) | |
| Present | 67 | 67 (16) | 0 (0) | |
| Monosomal karyotype, n (%) | <.001 | |||
| Absent | 459 | 359 (87) | 100 (98) | |
| Present | 58 | 56 (13) | 2 (2) | |
| NPM1, n (%) | .03 | |||
| Wild-type | 328 | 280 (77) | 48 (65) | |
| Mutated | 108 | 82 (23) | 26 (35) | |
| FLT3-ITD, n (%) | <.001 | |||
| Wild-type | 345 | 298 (81) | 47 (63) | |
| Mutated | 96 | 68 (19) | 28 (37) | |
| NPM1 and FLT3-ITD co-mutation, n (%) | .01 | |||
| NPM1 wild-type, FLT3-ITD negative | 281 | 246 (68) | 35 (47) | |
| NPM1 mutated, FLT3-ITD negative | 61 | 49 (14) | 12 (16) | |
| NPM1 wild-type, FLT3-ITD positive | 47 | 34 (9) | 13 (18) | |
| NPM1 mutated, FLT3-ITD positive | 45 | 31 (9) | 14 (19) | |
| CEBPAbiallelic, n (%) | .08 | |||
| Wild-type | 344 | 292 (99) | 52 (95) | |
| Mutated | 7 | 4 (1) | 3 (5) | |
| FLT3-ITD allelic ratio, n (%) | .23 | |||
| <0.5 | 46 | 36 (59) | 10 (43) | |
| ≥0.5 | 38 | 25 (41) | 13 (57) | |
| RUNX1, n (%) | .32 | |||
| Wild-type | 103 | 87 (86) | 16 (76) | |
| Mutated | 19 | 14 (14) | 5 (24) | |
| TP53, n (%) | >.99 | |||
| Wild-type | 109 | 90 (89) | 19 (90) | |
| Mutated | 13 | 11 (11) | 2 (10) | |
| ASXL1, n (%) | .73 | |||
| Wild-type | 114 | 94 (89) | 20 (87) | |
| Mutated | 15 | 12 (11) | 3 (13) | |
| Characteristics at HSCT | ||||
| Age at HSCT, y, median (range) | 59.6 (16.3-76.8) | 60.3 (16.3-76.0) | 59.6 (19.2-76.8) | .43 |
| Treatment cycles before HSCT, n (%) | <.001 | |||
| 1 | 157 | 72 (16) | 85 (71) | |
| 2 | 311 | 280 (61) | 31 (26) | |
| ≥3 | 111 | 107 (24) | 4 (3) | |
| Blood count regeneration at HSCT, n (%) | .41 | |||
| CR | 484 | 387 (84) | 97 (81) | |
| CRi | 96 | 73 (16) | 23 (19) | |
| MRD status at HSCT, n (%) | .10 | |||
| MRD− | 167 | 133 (58) | 34 (47) | |
| MRD+ | 133 | 95 (42) | 38 (53) | |
| Donor type, n (%) | .02 | |||
| Matched related | 124 | 109 (24) | 15 (13) | |
| Unrelated, HLA matched | 329 | 258 (56) | 71 (59) | |
| HLA mismatched | 112 | 80 (17) | 32 (27) | |
| Haploidentical | 14 | 12 (3) | 2 (2) | |
| Conditioning regimen, n (%) | .22 | |||
| NMA | 383 | 296 (64) | 87 (73) | |
| HSCT | 36 | 31 (7) | 5 (4) | |
| MAC | 161 | 133 (29) | 28 (23) | |
| HCT-CI score, n (%) | .59 | |||
| 0 | 244 | 195 (44) | 49 (42) | |
| 1 and 2 | 163 | 125 (26) | 38 (32) | |
| ≥3 | 159 | 129 (29) | 30 (26) | |
| CMV status, n (%) | .05 | |||
| Recipient+/donor− | 210 | 157 (35) | 53 (45) | |
| All others | 364 | 298 (65) | 66 (55) | |
| aGvHD ≥ grade 2, n (%) | .21 | |||
| Absent | 371 | 303 (74) | 68 (68) | |
| Present | 137 | 105 (26) | 32 (32) | |
| cGvHD, n (%) | .51 | |||
| Absent | 165 | 139 (41) | 26 (37) | |
| Limited | 58 | 45 (13) | 13 (19) | |
| Extended | 184 | 153 (45) | 31 (44) | |
| Donor sex, n (%) | .88 | |||
| All others | 489 | 388 (85) | 101 (86) | |
| Female into male | 82 | 66 (15) | 16 (14) | |
ASXL1, additional sex combs-like 1 gene; CEBPA, CCAAT/enhancer-binding protein α gene; CMV, cytomegalovirus; Hb, hemoglobin; HCT-CI, hematopoietic cell transplantation comorbidity index; NMA, nonmyeloablative conditioning; NPM1, nucleophosmin 1 gene; PB, peripheral blood; HSCT, reduced-intensity conditioning; RUNX1, runt-related transcription factor 1 gene; TP53, tumor protein 53 gene; WBC, white blood cell.